DarioHealth Corp Archives - Page 2 of 2

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.

Data shows improved outcomes with DarioHealth’s chronic condition management platform

DarioHealth (Nasdaq:DRIO) today announced real-world study data on the impact of managing diabetes and weight on a single digital platform.

New York-based DarioHealth presented the published retrospective, real-world study observing its digital therapeutics platform at the Advanced Technologies and Treatments for Diabetes (ATTD) Conference in Barcelona.

The company analyzed 12 months of data for a group of 715 individuals using the Dario app to manage their blood sugar aat a body mass index (BMI) of greater than 30 kg/m2, the clinical baseline for obesity. According to a news release, nearly two-thirds of DarioHealth participants in the study with a BMI of more than 30 reduced their BMI by an average of 2.8 units with an average weight loss of 7.4%.

A subgroup of Dario participants with BMIs greater than 30 and high-risk blood glucose readings of more than 180 mg/dL was observed as well to understand the impact on both diabetes and weight management. The…

DarioHealth agrees to acquire computer vision tech developer Physimax

DarioHealth (NSDQ:DRIO) announced today that it entered into an agreement to acquire Physimax Technologies.

Physimax develops computer vision (CV) technology for musculoskeletal (MSK) functional screening and predictive risk of injury assessment.

The technology is currently used commercially by National Basketball Association and National Football League teams, the U.S. military and healthcare facilities specializing in orthopedic care, according to a news release. Physimax’s offerings enable automated MSK and injury risk screenings with validated accuracy, while the company’s AI engine generates evidence-based personal training programs to aid in effective injury prevention and recovery.

In consideration for the acquisition of Physimax’s assets, the company agreed to issue up to 256,660 shares of its common stock, plus a cash payment of $500,000, along with an agreement to assume certain liabilities in an approximate amount of $1.02 mi…

DarioHealth unveils digital therapy for treating musculoskeletal conditions

DarioHealth (NSDQ:DRIO) announced that it launched Dario Move, a digital physical therapy platform for musculoskeletal (MSK) conditions.

With the introduction of the Dario Move, Boston-based Dario adds to its suite of chronic condition management platforms that include treatments for diabetes, behavioral health and metabolic health, according to a news release.

Dario Move combines software, technology and professional human support with features including a single biofeedback sensor for ease of use, personalized evidence-based exercise programs designed by physical therapists, real-time feedback and support and a highly personalized experience across Dario’s full suite of chronic condition solutions.

“The launch of Dario Move marks a significant achievement for our company, as we successfully and efficiently integrated the Upright MSK solution into our comprehensive multi-chronic condition digital therapeutics platform, further expanding its …

DarioHealth touts data for diabetes management platform

DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform.

New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine.

Get the full story at our sister site, Drug Delivery Business News.

DarioHealth touts research on digital therapeutics for diabetes patients

DarioHealth (NSDQ:DRIO) announced today that recently published research supports its digital therapeutic platform for type 2 diabetes.

New York-based DarioHealth published a new study through a letter to the editor in the Journal of Diabetes Science and Technology, according to a news release. The study observed participants using DarioHealth’s digital therapeutics for diabetes management, monitoring for both clinical and self-reported impact.

Get the full story at our sister site, Drug Delivery Business News.

MedTech 100 roundup: Turnaround for the industry?

A turgid month for the medtech industry might be drifting into the past after the past week indicated a slight turnaround as summer nears.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week at 107.74 points, marking a 1.4% rise from the 106.22-point mark set one week prior.

Having endured its largest slide of 2021 in recent weeks, the index is already demonstrating signs of a rebound after April brought the industry’s all-time best performance.

Despite the setbacks that have plagued the industry over the past month or so, medtech’s performance continues to reflect a rebound from the struggles brought on by the COVID-19 pandemic. Overall, it has registered a 16.7% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 73.4% increase from the mid-pandemic low of 62.13 (March 23, 2020).

The overall markets were on the opposite end of the spectrum over the p…

DarioHealth acquires PsyInnovations for $30M

DarioHealth announced that it entered into an agreement to acquire digital health company PsyInnovations for up to $30 million.

PsyInnovations develops the wayForward behavioral digital health platform with AI-enabled screening to triage and navigate members to specific interventions, digital cognitive behavioral therapy (CBT), self-directed care, expert coaching and access to in-person and telehealth provider visits, according to a news release.

Currently, wayForward provides its full suite of digital behavioral health services to approximately 20,000 members and 20 self-insured employers.

New York-based DarioHealth expects its acquisition of PsyInnovations and the wayForward platform to supplement its platform of digital therapeutics aimed at more easily changing behavior. DarioHealth’s platform covers diabetes, hypertension, pre-diabetes, musculoskeletal and behavioral health.

“Dario is a strong, flexible AI-driven platform that all…

DarioHealth partners with MediOrbis on virtual diabetes care platform

DarioHealth (NSDQ:DRIO) announced that it launched a new virtual care initiative with MediOrbis to improve virtual care for diabetes.

New York-based DarioHealth’s collaboration with MediOrbis is slated to offer eligible Medicare members with diabetes a convenient method for virtual care that includes MediOrbis’ telehealth offerings and DarioHealth’s AI-powered remote patient monitoring, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

DarioHealth ticks up before market opens on Q4 results

DarioHealth (NSDQ:DRIO) shares ticked up in pre-market trading today on fourth-quarter revenues that equaled the consensus forecast.

The New York-based digital therapeutics company posted losses of -$9 million for the three months ended Dec. 31, 2020, representing a more than doubled bottom-line slide from the same quarter last year on sales growth of 15.7%.

Get the full story at our sister site, Drug Delivery Business News.

DarioHealth raises $28.6M

DarioHealth (NSDQ:DRIO), a developer of digital therapeutics for chronic conditions, filed an SEC Form D to confirm the sale of more than $28 million.

The Israel-based company made its first sale in the new notice offering of equity and options, warrants and other rights to purchase securities on July 31. The offering is not being made in connection with a merger, acquisition or exchange offer, or anything of the like.

DarioHealth is offering $30 million in total, having already raised nearly $28.6 million with participation from 27 investors so far, according to the filing. There remains just $1.4 million left to be sold in the offering, which DarioHealth does not intend to last longer than one year.

Additionally, DarioHealth owes $910,224 in sales compensation, including $617,721 for Aegis Capital, along with warrants to purchase 10% of the aggregate number of securities sold.

The company did not list an intended use of proceeds in the filing da…

Abbott, Medtronic go head-to-head at ADA conference

Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology.

The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller companies as well as studies showing how diabetes tech is helping diverse patient populations. More than 800 sessions have been planned.

Here are some of the highlights of this year’s conference, which began June 12.

Next>>